E
Immutep Limited IMMP
$1.76 $0.063.53%
Recommendation
Sell
Prev Close
$1.70
Volume
10,793
Avg Vol (90D)
107,998
Market Cap
$251.64M
Dividend & Yield
--
52-Week Range
$1.65 - $3.34
P/E (TTM)
--
EPS (TTM)
-$0.0218
My Lists My Alerts
Rating
Reward
E
Very Weak
Risk
D-
Weak
Rating Factors
Growth Index
Fair
Efficiency Index
Very Weak
Solvency Index
Excellent
Total Return Index
Weak
Volatility Index
Weak
Dividend Index
--
Headlines
Immutep Ltd (PRRUF) Receives a Buy from Canaccord Genuity
3/7/2025 - TipRanks Financial Blog
Immutep Ltd Reports Increased Income Amid Rising R&D Costs
3/3/2025 - TipRanks Financial Blog
Immutep Reports Increased Revenue Amid Growing R&D Costs
3/3/2025 - TipRanks Financial Blog
Is Immutep Limited (IMMP) the Best Long Term ASX Stock to Buy Now?
2/11/2025 - Insider Monkey
10 Best Long Term ASX Stocks to Buy Now
2/11/2025 - Insider Monkey
Immutep Ltd Updates Stakeholders on Business Progress
2/5/2025 - TipRanks Financial Blog
Immutep Advances to Phase III with Key Approvals and Promising Trial Results
2/3/2025 - TipRanks Financial Blog
Immutep promotes Christian Mueller to CDO, CMO Florian Vogl to depart
1/31/2025 - TipRanks Financial Blog
Immutep promotes Christian Mueller to CDO, CMO Florian Vogl to depart
1/31/2025 - The Fly
Immutep reports Q2 cash receipts from customers A$8,000
1/31/2025 - The Fly
Immutep Quarterly Activities Report Q2 FY25
1/31/2025 - GuruFocus
Immutep Quarterly Activities Report Q2 FY25
1/31/2025 - Globe Newswire
Is Immutep Limited (IMMP) One of the Best ASX Stocks to Buy According to Hedge Funds?
1/31/2025 - Insider Monkey
10 Best ASX Stocks to Buy According to Hedge Funds
1/30/2025 - Insider Monkey
Immutep Limited: Continuing To Make The Case For Eftilagimod
1/28/2025 - Seeking Alpha - Long Ideas
Immutep Limited: Continuing To Make The Case For Eftilagimod
1/28/2025 - SeekingAlpha
10 Best Australian Stocks to Buy Now
1/26/2025 - Insider Monkey
Immutep announces patient enrollment completed for EFTISARC-NEO Phase II trial
1/22/2025 - The Fly
Patient Enrolment Completed for EFTISARC-NEO Phase II Trial
1/22/2025 - Globe Newswire
Immutep (NASDAQ:IMMP) Stock Passes Below Fifty Day Moving Average - What's Next?
1/22/2025 - MarketBeat
Immutep (NASDAQ:IMMP) Share Price Crosses Below Fifty Day Moving Average - Should You Sell?
1/14/2025 - MarketBeat
Immutep (NASDAQ:IMMP) Stock Price Crosses Below 50-Day Moving Average - Time to Sell?
1/14/2025 - Ticker Report
Immutep completes patient enrollment for INSIGHT-003
1/6/2025 - The Fly
Patient Enrolment Completed for INSIGHT-003
1/6/2025 - Globe Newswire
Immutep Completes Enrolment for Promising INSIGHT-003 Cancer Trial
1/5/2025 - TipRanks Financial Blog
Income Statement
Total Revenue (TTM)
$3.22M
EBITDA (TTM)
-$32.23M
EBIT (TTM)
-$32.88M
Net Income (TTM)
-$28.93M
Balance Sheet
Total Assets (Q)
$112.83M
Total Debt (Q)
$1.04M
Total Liabilities (Q)
$6.10M
Book Value Per Share (Q)
$0.0733
Cash Flow
Cash from Operations (TTM)
-$29.64M
Cash from Investing (TTM)
-$55.07M
Cash from Financing (TTM)
$62.66M
Net Change in Cash (TTM)
-$19.87M
Filings
Filing Date
Wednesday, February 26, 2025
Period Date
Tuesday, December 31, 2024
Next Filing
Week of Aug 25 and 29 (est)
Price History
Loading...
Beta
1.26
7-Day Total Return
-2.22%
30-Day Total Return
-14.15%
60-Day Total Return
-21.25%
90-Day Total Return
-9.74%
Year to Date Total Return
-20.36%
1-Year Total Return
-32.57%
2-Year Total Return
6.02%
3-Year Total Return
-30.16%
5-Year Total Return
-7.85%
52-week Low
Mar 12, 2025 - $1.65
52-week High
May 21, 2024 - $3.34
Valuation
Market Cap
$251.64M - Micro Cap
Enterprise Value
$152.58M
Price/Sales (TTM)
772.73
Price/Book (Q)
23.19
Dividends and Shares
Shares Outstanding
1.45B
Dividend Per Share (Most Recent)
--
Dividend Per Share (TTM)
--
Corporate Info
Website
www.immutep.com
Phone Number
61 2 8315 7003
Address
Australia Square
Level 32 - 264 George Street
Sydney, NSW 2000
Country
Australia
Year Founded
1987
Business Description
Sector
Health Care
Industry
Pharmaceuticals, Biotechnology and Life Sciences
Immutep Limited, a late-stage biotechnology company, engages in developing novel LAG-3 related immunotherapies for cancer and autoimmune diseases in Australia. Its lead product candidate is the... more
NASDAQ 03/13/2025 10:09AM Eastern Quotes delayed
Weiss Ratings